Year: 2020
Type: article
Abstract: This literature review was carried out based on the completed of an Objective Structured Clinical Examination (OSCE) and oral defense.After reviewing the case report, the topic of precision medicine and the treatment of type II diabetes was selected.Using CINAHL Complete and PubMed, a search was conducted using the controlled vocabulary terms precision medicine, pharmacogenetics, genetically guided therapy, type II diabetes, and diabetes mellitus type II.The search terms were connected using the Boolean connectors AND and OR.The search was further refined using the following criteria: published between 1/1/2015 and 12/31/2020, English language, peer-reviewed, and human.Guidelines from the American Association of Clinical Endocrinologists and the American Diabetes Association were reviewed for current recommendations on second-line treatment recommendations for type II diabetes.The literature review shows precision medicine for the treatment of type II diabetes has started with monogenic diabetes and neonatal diabetes as well as specific genetic markers that may indicate patient response to second-line medications.The most impactful advancement of type II diabetes management through precision medicine is the sub stratification of diabetes into five subgroups and their associated genetic makeup and risk of complications.It also outlines that precision medicine also includes lifestyle intervention as well as machine learning.Further research is needed before implementation within healthcare regarding genomic markers, cost feasibility, and transferability across healthcare organizations.
Author: Emily Stunek
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W3021449314
